Defining Drugs that are High-Risk Associations for Drug Reactions Within the Hospital Setting.
DRESS Syndrome
Drug eruption
medical dermatology
Journal
The Journal of clinical and aesthetic dermatology
ISSN: 1941-2789
Titre abrégé: J Clin Aesthet Dermatol
Pays: United States
ID NLM: 101518173
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
6
7
2022
Statut:
ppublish
Résumé
We sought to evaluate medication exposures during an entire hospitalization, with the goal of describing medications and demographic conditions that are associated with developing a drug eruption during hospitalization. 468 patients that developed a cutaneous drug eruption were identified from a cohort of 18,140 unique inpatients with dermatologic diagnoses; medication lists and demographic information were assimilated, and drug eruption frequency tables were created. The agents most commonly associated with drug eruptions included many antineoplastic, antifungal, and antibiotic therapeutics: idarubicin (27.78% reaction rate), daunorubicin (26.43%), sorafenib (25.00%), lenalidomide (23.53%), all-trans-retinoic acid (22.58%), decitabine (21.57%), aztreonam (15.15%), posaconazole (14.29%), and voriconazole (13.78%) among many others. Patients diagnosed with drug eruptions were more likely to have private insurance (3.29% vs. 2.58% reaction rate) and were on average older (56.7 vs. 52.6 years), had longer inpatient stay (14.2 vs. 7.9 days), and higher inpatient mortality (5.95% vs. 2.58%) than patients without eruptions. This was a single-center cross-sectional study. Drug reaction codes were used substantially less frequently than more general codes for non-specific eruptions, further, the analysis was stratified by full hospitalization data to account for delayed reactions. Hospitalizations in which patients receive medications common to malignancies, such as cytotoxic and antifungal therapies represent the highest risk hospitalizations for the development of drug eruptions. When diagnosing and treating drug eruptions, clinicians should consider these medication classes with a high index of suspicion.
Types de publication
Journal Article
Langues
eng
Pagination
59-64Informations de copyright
Copyright © 2022. Matrix Medical Communications. All rights reserved.
Déclaration de conflit d'intérêts
DISCLOSURES.: The authors report no conflicts of interest relevant to the content of this article.
Références
J Am Acad Dermatol. 2015 Nov;73(5):821-8
pubmed: 26321388
J Eur Acad Dermatol Venereol. 2002 Sep;16(5):481-5
pubmed: 12428842
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
BMC Syst Biol. 2017 Oct 3;11(Suppl 5):87
pubmed: 28984210
Curr Oncol Rep. 2008 Jul;10(4):309-18
pubmed: 18778557
J Allergy Clin Immunol. 2012 Feb;129(2):566-7
pubmed: 22035657
Int J Dermatol. 2019 May;58(5):e109-e110
pubmed: 30478890
Arch Dermatol. 1994 Aug;130(8):1022-5
pubmed: 8053699
J Clin Pharm Ther. 1998 Apr;23(2):149-54
pubmed: 9786102
Oncologist. 2003;8(2):187-98
pubmed: 12697943
Yearb Med Inform. 2016 May 20;Suppl 1:S48-61
pubmed: 27199197
J Am Acad Dermatol. 2008 Dec;59(6):995-9
pubmed: 19022101
JAMA. 1986 Dec 26;256(24):3358-63
pubmed: 2946876
Ther Adv Med Oncol. 2010 Jan;2(1):51-63
pubmed: 21789126
N Z Med J. 1995 May 10;108(999):165-6
pubmed: 7753511
Int J Dermatol. 2020 Jun;59(6):647-655
pubmed: 31681983